We use cookies to give you the best online experience. By using our website you agree to our use of cookies in accordance with our cookie policy. Learn more

Link to third party site

The link you have selected will take you away from this site to one that is not owned or controlled by Roche, F. Hoffmann-La Roche Ltd makes no representation as to the accuracy of the information contained on sites we do not own or control. Roche does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.

364 Search Results

Effect of emicizumab on global coagulation assays for plasma supplemented with apixaban or argatroban

Tripodi A, Chantarangkul V, Padovan L, Clerici M, Scalambrino E, Peyvandi F. J Thromb Thrombolysis. 2020;49(3):413-419.

Recurrence of a high-titre factor VIII inhibitor in a haemophilia A patient on emicizumab prophylaxis

Doshi BS, Witmer CM. Haemophilia. 2021 Jul;27(4):e551-e553

Emicizumab for hemophilia A without inhibitors

Cafuir L, Kruse-Jarres R, Mancuso ME, Kempton CL. Expert Rev Hematol. 2019;12(7):515-524.

Evaluating the safety of emicizumab in patients with hemophilia A

Langer AL, Etra A, Aledort L. Expert Opin Drug Saf. 2018;17(12):1233-1237.

Emicizumab and thrombosis: The story so far.

Makris M, Iorio A, Lenting PJ. J Thromb Haemost 2019;17:1269–1272.    

Prediction of the haemostatic effects of bypassing therapy using comprehensive coagulation assays in emicizumab prophylaxis‐treated haemophilia A patients with inhibitors

Furukawa S, Nogami K, Shimonishi N, Nakajima Y, Matsumoto T, Shima M. Br J Haematol. 2020 Sep;190(5):727-735

Identification and Multidimensional Optimization of an Asymmetric Bispecific IgG Antibody Mimicking the Function of Factor VIII Cofactor Activity

Sampei Z, Igawa T, Soeda T, et al. PLoS One. 2013;8(2):e57479.

Bispecific antibodies for the treatment of hemophilia A

Shima M. Expert Opin Biol Ther. 2021 Jun 17:1-14

Case report of a fatal rectal haemorrhage in a person with severe haemophilia A receiving emicizumab and high‐dose bypassing agents in the HAVEN 1 study

Khoo L, Matthews S, Kershaw G, et al. Haemophilia. 2020 Nov;26(6):e340-e342

Bispecific Antibody Emicizumab for Haemophilia A: A Breakthrough for Patients with Inhibitors

Mahlangu JN. BioDrugs. 2018;32(6):561-570.